Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY2951742 in Healthy Volunteers
- First Posted Date
- 2011-04-19
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 63
- Registration Number
- NCT01337596
- Locations
- 🇧🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium
A First Human Study of a Ferroportin Antibody
- First Posted Date
- 2011-04-07
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT01330953
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
A Study of the Effect of LY2189265 on Two Blood Pressure Drugs
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 51
- Registration Number
- NCT01324388
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
A Study of LY2828360 in Patients With Osteoarthritic Knee Pain
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 39
- Registration Number
- NCT01319929
- Locations
- 🇩🇰
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalborg, Denmark
A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors
- Conditions
- Gastrointestinal Stromal Tumor (GIST)
- Interventions
- Biological: Olaratumab
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 21
- Registration Number
- NCT01316263
- Locations
- 🇪🇸
ImClone Investigational Site, Madrid, Spain
A Study to Compare Two Forms of LY2608204 in Healthy People
- Conditions
- Healthy Volunteers
- Interventions
- Drug: LY2608204 ReferenceDrug: LY2608204 Test
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2018-10-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT01313286
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Biological: LY2189265
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT01301092
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States
Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-02-21
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT01300260
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany
Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects
- First Posted Date
- 2011-02-18
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6
- Registration Number
- NCT01299285
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States
A Study in Prevention of Re-emergence of Depression Symptoms
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2011-02-18
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1249
- Registration Number
- NCT01299272
- Locations
- 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Diyarbakir, Turkey